If FDA clearance or CE marking is pending, you can still assess whether a specific Asia-Pacific market deserves further investment. This article explains how MedTech and medical device founders can test APAC market entry before committing more time and budget.
When you get there, will you know which customers are likely to buy, how they decide, and what it will take to win their orders?
Selected Asia-Pacific (APAC) markets may offer regulatory pathways worth assessing while another process continues. But regulatory eligibility is not market access. Market access is not customer demand. And customer interest is not a purchase order.
Do not enter APAC just because another regulatory milestone is pending. Test whether a specific market merits further time and investment.
Two scenarios. One commercial decision.
Scenario A: CE marking obtained. FDA clearance pending.
Could you test customer demand in a selected APAC market while your US regulatory process continues?
The question is not whether to abandon the US market. It is whether focused market research could reveal a worthwhile opportunity before you commit additional resources.
Singapore and Malaysia may be worth examining, depending on your device and its existing regulatory validation. Singapore’s Health Sciences Authority (HSA) provides defined registration evaluation routes that can recognise certain overseas validation, including specified EU Notified Body certificates for eligible devices. CE marking alone does not guarantee eligibility or registration. [1]
Malaysia offers a conformity-assessment route by way of verification for eligible devices supported by recognised foreign approvals. This is a defined process within Malaysia’s framework—not automatic permission to market. [2]
India and Sri Lanka have their own requirements. Existing foreign validation may be relevant, but it does not replace local rules. [3] [4]
The commercial question is not which country looks easiest to enter. It is whether you can identify customers with a relevant need, understand how they buy, assess the available channel, and build a credible case for further investment.
Scenario B: FDA clearance obtained. CE marking pending.
Must your next commercial opportunity wait for Europe?
Depending on your device and local requirements, another market may be worth investigating while your European process continues.
FDA decisions are not interchangeable. A 510(k) results in clearance, a De Novo can result in marketing authorisation, and a PMA can result in approval. The precise status of your device matters when assessing whether its validation may support an overseas route.
Singapore’s evaluation routes recognise specified US FDA decisions for eligible devices. Malaysia has a defined verification process for eligible devices supported by recognised foreign approvals. Availability depends on the device, the validation and local requirements—not simply on holding an FDA clearance or approval. [1] [2]
India and Sri Lanka must be assessed against their own rules. An FDA decision alone does not establish permission to market. [3] [4]
In both scenarios the commercial question is the same: can you establish enough validation of customer demand and purchasing readiness to justify the next investment? You do not need to assume the answer is yes. The purpose of this market assessment is to find out.
Five questions to test before committing more capital
You can assess commercial potential without assuming you are authorised to import, demonstrate, evaluate, supply or sell the device. What is permitted before local authorisation depends on the market and the activity. Verify the applicable requirements before proceeding.
1. Who has a problem worth solving?
Start with three target accounts as a practical first step in customer research—not as a representative market sample or proof of demand.
Identify hospitals or healthcare providers most likely to experience the clinical problem your device addresses. Across those accounts, test these questions:
- What problem are they trying to solve, and how do they address it today?
- Who experiences the problem, and who would champion a potential solution?
- Who controls the budget and influences the purchasing decision?
- What alternatives are already available?
- Why might the account choose your product rather than an existing option?
Do not stop at whether a clinician likes your product. Find out whether the problem matters enough for the organisation to consider changing its current practice, allocating resources or purchasing a different solution.
The objective is not to collect meetings or expressions of interest. It is to understand whether a specific customer has a meaningful need and a credible reason to consider your product.
2. What would make a purchase possible?
Clinical interest does not automatically become a purchase order.
Find out what must happen between a clinician recognising a need and an organisation approving a purchase. Understand what the clinical champion, budget owner and procurement team need to see before a purchase can proceed. Understand the purchasing process, budget availability, decision criteria and likely timeline.
Ask what could prevent a purchase even if the product is clinically relevant:
- Is there an identified budget?
- Does procurement require additional validation?
- Who needs to approve the purchase?
- What conditions must be met before the organisation can proceed?
You should leave this stage knowing which requirements are understood, which remain untested, and what validation is needed next.
3. Can the channel generate repeat purchasing?
A medical device distributor agreeing to represent your product is not, by itself, validation that it can sell it successfully.
Assess whether a prospective channel partner can:
- Reach the hospitals and decision-makers that matter
- Explain the product’s relevance to customer needs
- Support the product appropriately after a sale
- Navigate the local buying process
- Develop repeat purchasing rather than rely on an initial stocking order
A distributor may have a strong reputation and an established portfolio but limited access to the specific buyers your product needs. It may also be capable of securing an initial order without the resources or relationships to generate ongoing demand.
The question is not simply whether a distributor wants your product. It is whether the channel can help create and sustain customer demand.
4. What could stop interest becoming an order?
A customer may acknowledge a clinical need, attend a meeting or express interest without ever buying.
Identify the barriers between interest and purchase. Could the price exceed the available budget? Is the budget owner involved? Does procurement require additional validation? Are reimbursement, service, training or implementation requirements unresolved? Is a competing product already meeting the need?
Distinguish between barriers you can address and those that could make the opportunity commercially unattractive. A clinician may support your product, but the hospital may have no budget, an established supplier agreement, or no immediate reason to change.
A promising conversation becomes a more credible opportunity only when you understand what must happen next, who needs to act, and what could still prevent the order.
5. What validation justifies further investment?
Before committing more capital, determine what you need to learn about the market, customer segment and channel. Estimate the resources required, including market development, distributor support, local capabilities and other commercial costs.
Then define the validation that would justify the next step. For example:
- Confirmation of a specific customer need
- Access to the budget owner or procurement decision-maker
- A confirmed purchasing process and realistic timeline
- Validation that the product offers a meaningful advantage over existing alternatives
- Validation that a distributor can reach and support the right accounts
- A clearer understanding of the requirements, costs and resources needed
Be explicit about what would change your decision. The goal is not to prove that APAC is attractive. It is to establish whether the validation supports investing further.
What should APAC demand validation produce?
At the end of the exercise you should have more than a list of interested accounts or prospective distributors. You should have a clear commercial decision, supported by validation and explicit assumptions.
GO — Pursue the next stage.
There is sufficient validation of a relevant customer need, a plausible buying process and a credible route to pursue the opportunity. Identify the remaining requirements and the next investment needed.
PAUSE — Test the critical assumption.
The opportunity may be attractive, but a key assumption remains untested. Define what validation is missing and how to obtain it before committing further resources.
STOP OR REDIRECT — Reconsider the opportunity.
Validation suggests that the market, customer segment or channel is unlikely to justify the investment. Reconsider the target market, buyer, product positioning or route to market.
Three target accounts can help expose assumptions, but they cannot establish market-wide demand. A positive meeting is an early signal—not proof of a likely purchase.
The quality of the decision depends on what you learn: who needs the product, who can authorise the purchase, how the buying process works, what could prevent an order, and what remains unproven.
The market assessment may identify a credible next step even if a sale cannot yet lawfully take place. Do not treat demonstrations, evaluations or clinical research as automatic shortcuts to commercial validation. These activities carry separate requirements covering authorisation, importation, ethics, study conduct and other conditions. Confirm the applicable rules before undertaking any activity. [5] [6] [7]
Before your next regulatory milestone, test the go-to-market case
APAC is not automatically the answer for a MedTech company waiting for FDA clearance or CE marking. But waiting for a regulatory decision does not mean waiting to test customer demand.
Use the time to understand which customers have a relevant need, how they buy, whether the channel can reach and support them, and what validation would justify further investment.
The objective is not simply to enter another market. It is to determine whether there is a credible path from customer need to hospital purchase orders—and whether that opportunity deserves more capital.
What is the smallest next investment that could tell you whether this opportunity is worth pursuing?
If you have hospital interest or distributor discussions but no clear path to purchase orders, book a free 30-minute call to discuss the commercial gaps and what to test next.
Important note: Regulatory information is subject to change. The routes described are conditional and may not apply to every device. Founders and investors should verify current, device-specific requirements with the relevant authorities and qualified local advisers before acting. This article provides general commercial information and does not constitute regulatory or legal advice.
References
[1] Singapore — Health Sciences Authority (HSA)
GN-15, Guidance on Medical Device Product Registration, Revision 14 (September 2026). This guidance describes registration evaluation routes and qualifying overseas regulatory validation, subject to device classification, labelled use, certificate type and the applicable route conditions.
- Registration overview
- Current medical-device guidance documents
- GN-15 Revision 14 — September 2026 (PDF available via the guidance documents page)
[2] Malaysia — Medical Device Authority (MDA)
MDA/GD/0068, Conformity Assessment Body Guide for Conducting Conformity Assessment by Way of Verification, Second Edition (17 September 2025); and MDA/GD/0070, Medical Device Registration Submission Guide for Conformity Assessment by Way of Verification Process and Submission of Application in MeDC@St, Second Edition (13 October 2025). Read these documents alongside the applicable Malaysian laws, regulations and current guidance on recognised foreign approvals.
- Current MDA guidance documents
- MDA/GD/0068 — official notice
- MDA/GD/0070 — available via the guidance documents index
[3] India — Central Drugs Standard Control Organization (CDSCO)
Medical Devices Rules, 2017, as amended. Consult the current official rules and applicable requirements for the specific device and proposed route.
[4] Sri Lanka — National Medicines Regulatory Authority (NMRA)
Consult NMRA’s current medical-device registration guidelines and applicable requirements for the specific device. Foreign manufacturers apply through a local Marketing Authorisation Holder.
[5] Malaysia — Medical Device Authority (MDA)
Guidance on importing and/or supplying unregistered medical devices for demonstration for marketing or education purposes. Confirm that the proposed activity falls within the applicable provisions.
- Available via MDA guidance documents
[6] Singapore — Health Sciences Authority (HSA)
Guidance on importing unregistered medical devices for exhibition. Approval is required before import, and the devices are restricted to the permitted exhibition purpose.
- Available via HSA medical devices guidance documents
[7] Singapore — Health Sciences Authority (HSA)
Guidance on clinical research materials, including requirements applicable to the import or supply of medical devices for clinical research. Check the requirements for the proposed research activity.
- Available via HSA medical devices guidance documents